Eliminate the dead angles in the patient’s trip

It is of a large overview of the patient diagnosis course for treatment is of great interest for drug developers because they aspire to produce more effective drugs. The use of non -small cell (NSCLC) lung cancer as an example, Purlelab and Genentech will explore how to exploit the RWD to eliminate the dead angles in the patient’s trip – Informing each phase of the life cycle of a drug, from clinical development to market access.

The webinar will include executives from Purlelab and Dr. Ben Freiberg, the main computer systems lead with the GCS computer catalysts from Genentech. Genentech belongs to Roche.

Among the discussion points that the webinar will cover, there is:

• How can RWDs be operated by pharmaceutical companies for the course of NSCLC patients?
• What is the “typical” patient for the CNPPRS?
• Cartography of the nuanced parts of a patient’s trip
• The value of taking advantage of the social determinants of health data
• Approach the socio-economic obstacles that can hinder the participation of clinical trials
• Use of RWD to improve the recruitment of clinical trials, clinical termination criteria and clarify market access strategies

To register for the webinar eliminating the dead angles in the patient’s journey, scheduled for 1:00 p.m. on May 22, please fill out the form below:

Photo: Eugene Mymrin, Getty Images